Meridian Bioscience Inc
NASDAQ:VIVO
Meridian Bioscience Inc
Gross Profit
Meridian Bioscience Inc
Gross Profit Peer Comparison
Competitive Gross Profit Analysis
Latest Figures & CAGR of Competitors
Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Meridian Bioscience Inc
NASDAQ:VIVO
|
Gross Profit
$188.4m
|
CAGR 3-Years
17%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
Cooper Companies Inc
NYSE:COO
|
Gross Profit
$2.4B
|
CAGR 3-Years
16%
|
CAGR 5-Years
8%
|
CAGR 10-Years
9%
|
|
DENTSPLY SIRONA Inc
NASDAQ:XRAY
|
Gross Profit
$2.1B
|
CAGR 3-Years
6%
|
CAGR 5-Years
0%
|
CAGR 10-Years
3%
|
|
Align Technology Inc
NASDAQ:ALGN
|
Gross Profit
$2.7B
|
CAGR 3-Years
10%
|
CAGR 5-Years
13%
|
CAGR 10-Years
18%
|
|
Lantheus Holdings Inc
NASDAQ:LNTH
|
Gross Profit
$874.3m
|
CAGR 3-Years
82%
|
CAGR 5-Years
38%
|
CAGR 10-Years
26%
|
See Also
What is Meridian Bioscience Inc's Gross Profit?
Gross Profit
188.4m
USD
Based on the financial report for Sep 30, 2022, Meridian Bioscience Inc's Gross Profit amounts to 188.4m USD.
What is Meridian Bioscience Inc's Gross Profit growth rate?
Gross Profit CAGR 5Y
9%
Over the last year, the Gross Profit growth was -6%. The average annual Gross Profit growth rates for Meridian Bioscience Inc have been 17% over the past three years , 9% over the past five years .